All insulin manufacturers must price insulin pens at a dollar each in low- and middle-income countries

AMR remains a leading cause of death worldwide nearly a decade after UN member states agreed to make it a priority

MSF responds to WHO recommendation of three new regimens of shorter, all-oral TB regimens, outlines the importance of affordable access to these regimens.

MSF responds to WHO declaring mpox a PHEIC, outlines need for all components of an outbreak response and offers concrete actions to improve access and use of existing vaccines.

There were an estimated 1.3 million new HIV infections in 2023, but ViiV distributed only enough CAB-LA for approximately 13,000 people in 2023

Time for $5 campaign demands Cepheid reduce price of HIV, TB and hepatitis C tests to $5 each

MSF calls on pharmaceutical corporation Gilead to make groundbreaking HIV prevention drug lenacapavir affordable for all

Indian Patent Office’s rejection of J&J’s patent application on lifesaving paediatric TB drug bedaquiline significant step for increasing affordable access.

MSF urges WHO member states to commit to stronger obligations

MSF welcomes withdrawal of patents on TB drug bedaquiline in South Africa

Time for $5 campaign: Open letter to Danaher employees

Following GeneXpert TB test price reduction, several low- and middle-income countries’ Ministries of Health request the same price reduction of other tests.